
Hepatx
Hepatx is a YC Summer 2018 (S18) company. Based in Palo Alto, CA, USA. Team of 4.
About Hepatx
Summary
Hepatx develops off-the-shelf, stem cell-based therapies for patients with end-stage liver disease, positioning the treatment as a direct alternative to liver transplant. The therapy targets the roughly 200,000 Americans each year who reach end-stage liver failure and face a severe shortage of donor organs. The work it replaces is organ transplant surgery, along with the prolonged waiting and high mortality that comes with relying on donor availability.
Business model
Cell therapy treatments sold as off-the-shelf infusion products to replace organ transplant procedures.
Go-to-market
Hepatx targets late-stage liver disease patients who cannot access a donor organ in time, with a scalable manufacturing process designed to make the therapy practical for broad clinical deployment.
From the Y Combinator listing
Replacing organ transplant with an infusion
Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.
Facts
- Healthcare / Healthcare -> Therapeutics
- Palo Alto, CA, USA
- 4
- Active
- Early
Founders (1)
- Eric Schuur
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works